Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset....
Hence then, the article about boehringer ingelheim and simcere partner to advance a dual target antibody treatment to address unmet needs in inflammatory bowel disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease )
Also on site :
- Sydney Sweeney Goes Viral for Racy New Ad Showing Off Nude Appearance: ‘She’s Got the Whole Internet Malfunctioning… AGAIN’
- Dolly Parton Filmed Her SongTeller Welcome Before She Left Us — On September 29 She’ll Still Be in Nashville to Greet You
- Linda Ronstadt’s 1999 Collaboration, a Cover of a Neil Young Classic, Charts for the First Time 27 Years Later